While targeting TGFβR2-mutant tumors exposes vulnerabilities to stromal TGF-β blockade in pancreatic cancer, canonical TGF-β signaling suppresses epithelial pancreatic cancer (PDA) cell proliferation, and as a result, inhibiting TGF-β has not been successful [11]. Here, TGFB1 is linked to Patent ductus arteriosus.